![Anwen Williams](https://profiles-cardiff.imgix.net/attachments/2639?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwyg
As an ambassador of Cardiff University’s ambition for excellence, I have an established international reputation and a distinguished track record of research in Experimental Pharmacology and Therapeutics.
As Director of Postgraduate Research Studies and Deputy Dean of Research, I provide academic leadership of policy and methodology that ties the managerial to the pedagogical in a way that benefits both students and staff in the School of Medicine. I successfully overhauled the teaching and learning strategy for postgraduate research studies in the School by leading several academic teams whose collegiality and productivity delivered a ‘transformational agenda’ for quality enhancement. My teaching and scholarship profile is distinguished by Higher Education Academy recognition at Senior Fellow level. This prestigious National accreditation was awarded for proven excellent professional practice and accomplishments in the management and leadership of postgraduate research provision. Consistent with student expectations, these activities contribute substantially to enhancing the environment for creativity and curiosity in the School of Medicine at Cardiff University.
Cyhoeddiad
2023
- Morrin, A. S., Eastham, S., Williams, A. S. and Jones, G. W. 2023. Tracking cardiovascular comorbidity in models of chronic inflammatory disease. In: Jenkins, B. J. ed. Inflammation and Cancer., Vol. 2691. Methods in Molecular Biology New York, NY, USA: Springer, pp. 123-137., (10.1007/978-1-0716-3331-1_10)
2022
- Gillespie, D. et al. 2022. PrEP use, sexual behaviour, and PrEP adherence among men who have sex with men living in Wales prior to and during the COVID-19 pandemic. AIDS and Behavior 26, pp. 2746-2757. (10.1007/s10461-022-03618-4)
2021
- Davies, R. et al. 2021. The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology 60(6), pp. 2852-2861., article number: keaa725. (10.1093/rheumatology/keaa725)
2020
- Bonnet, C. S., Gilbert, S. J., Blain, E. J., Williams, A. S. and Mason, D. J. 2020. AMPA/kainate glutamate receptor antagonists prevent posttraumatic osteoarthritis. JCI Insight 5(13), article number: e134055. (10.1172/jci.insight.134055)
- Thompson, C., Davies, R., Williams, A., Jones, G. and Choy, E. H. S. 2020. CD28− Cells are increased in early rheumatoid arthritis and are linked with cytomegalovirus status. Frontiers in Medicine 7, article number: 129. (10.3389/fmed.2020.00129)
2019
- Collins, F. L., Stone, M. D., Turton, J., McCabe, L. R., Wang, E. C. and Williams, A. S. 2019. Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels. BMC Musculoskeletal Disorders 20(1), article number: 326. (10.1186/s12891-019-2704-z)
- Williams, A., Jones, M. G., Jonsson, R., Harris, R. A. and Mulvany, M. J. 2019. A comparison of doctoral training in biomedicine and medicine for some UK and Scandinavian graduate programmes: Learning from each other. FEBS Open Bio 9(5), pp. 830-839. (10.1002/2211-5463.12629)
- Williams, A., Powell, A. G., Spernaes, I., Basu, P., Edwards, S. and Edwards, P. 2019. Mode of presentation rather than the 'weekend effect' is a major determinant of in-hospital mortality. Surgeon 17(1), pp. 15-18. (10.1016/j.surge.2018.04.007)
2018
- Jordan, L. A. et al. 2018. Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis. Rheumatology 57(11), pp. 2042-2052. (10.1093/rheumatology/key196)
- Tonks, A. J. and Williams, A. S. 2018. Identifying unmet training needs for postgraduate research students in the biomedical sciences through audit of examiners' reports. International Journal of Doctoral Studies 13, pp. 169-191. (10.28945/4003)
- Jones, G., Hill, D., Sime, K. and Williams, A. 2018. In Vivo models for inflammatory arthritis. In: Jenkins, B. ed. Inflammation and Cancer. Methods in Molecular Biology., Vol. 1725. Methods in Molecular Biology New York, NY: Humana Press, pp. 101-118., (10.1007/978-1-4939-7568-6_9)
2017
- Colbeck, E. J. et al. 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5(11), pp. 1005-1015. (10.1158/2326-6066.CIR-17-0131)
- Singh, R. et al. 2017. Death receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation. Cellular Immunology 320, pp. 62-70. (10.1016/j.cellimm.2017.09.005)
- Sime, K., Choy, E. and Williams, A. 2017. Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice. Adipocyte 6(2), pp. 87-101. (10.1080/21623945.2017.1295174)
- Collins, F. L. et al. 2017. CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss. Bone 97, pp. 94-104. (10.1016/j.bone.2017.01.002)
2016
- Williams, A., Wang, E. C. Y., Thurner, L. and Liu, C. 2016. Novel insights into TNF receptor, DR3 and progranulin pathways in arthritis and bone remodeling. Arthritis & Rheumatology 68(12), pp. 2845-2856. (10.1002/art.39816)
- Perks, W. V. et al. 2016. Death Receptor 3 promotes chemokine directed leukocyte recruitment in acute resolving inflammation and is essential for pathological development of mesothelial fibrosis in chronic disease. American Journal of Pathology 186(11), pp. 2813-2823. (10.1016/j.ajpath.2016.07.021)
- Williams, J., Wang, E. C. Y., Lang, D. and Williams, A. S. 2016. Characterisation of Death Receptor 3 dependent aortic changes during inflammatory arthritis. Pharmacology Research & Perspectives 4(4), article number: e0024. (10.1002/prp2.240)
- Knight, J. C., Paisey, S. J., Dabkowski, A. M., Marculescu, C., Williams, A. S., Marshall, C. and Cornelissen, B. 2016. Scaling-down antibody radiolabeling reactions with zirconium-89. Dalton Transactions 45(15), pp. 6343-6347. (10.1039/C5DT04774A)
- Davies, R. et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55(Supp 1), pp. 54-54., article number: O41. (10.1093/rheumatology/kew102.004)
- Harvey, A. K. et al. 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2(2), article number: 33. (10.23937/2469-5726/1510033)
- Bloom, A. C. et al. 2016. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84, pp. 253-261. (10.1016/j.bone.2015.12.014)
2015
- Jones, G. W. et al. 2015. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. Journal of Experimental Medicine 212(11), pp. 1793-1802. (10.1084/jem.20132307)
2014
- Bonnet, C. S., Williams, A. S., Gilbert, S. J., Harvey, A. K., Evans, B. A. and Mason, D. J. 2014. AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Annals of the Rheumatic Diseases 74, pp. 242-251. (10.1136/annrheumdis-2013-203670)
- Wang, E. C. Y. et al. 2014. Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis and Rheumatology 66(10), pp. 2762-2772. (10.1002/art.38770)
- Greenhill, C. J. et al. 2014. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy 16(4), article number: 419. (10.1186/s13075-014-0419-y)
- Kehoe, O. et al. 2014. Syndecan-3 is selectively pro-inflammatory in the joint and contributes to antigen-induced arthritis in mice. Arthritis Research and Therapy 16(4), pp. 1-14., article number: R148. (10.1186/ar4610)
2013
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Jones, G. W., Greenhill, C. J., Williams, J. O., Nowell, M. A., Williams, A. S., Jenkins, B. J. and Jones, S. A. 2013. Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. Annals of the Rheumatic Diseases 72(10), pp. 1738-1742. (10.1136/annrheumdis-2013-203771)
- Greenhill, C. J. et al. 2013. Interleukin 10 control of the inflammasome restricts arthritic bone erosion [Abstract]. Cytokine 63(3), pp. 267. (10.1016/j.cyto.2013.06.105)
- Moideen, A. N. et al. 2013. Characterization of enzymes involved in nicotinamide adenine dinucleotide biosynthesis in rheumatoid arthritis synovium and cytokine-stimulated synovial fibroblasts [Abstracts]. Rhuematology 52(s1), pp. 138-139.
2012
- Reynolds, S. L. et al. 2012. Contractile, but not endothelial, dysfunction in early inflammatory arthritis: a possible role for matrix metalloproteinase-9. British Journal of Pharmacology 167(3), pp. 505-514. (10.1111/j.1476-5381.2012.01988.x)
- Collins, F., Stone, M. D., Goodfellow, R. M., Choy, E. H. S., Wang, E. C. Y. and Williams, A. S. 2012. TNF-like protein 1A/death receptor 3 pathway regulates osteoclastogenesis and is associated with erosive disease in rheumatoid arthritis. Arthritis and Rheumatism 64(10), pp. S768-S768.
- Greenhill, C. J. et al. 2012. Cross-talk between IL-10 and the inflammasome regulates bone erosions during rheumatoid arthritis [Abstract]. Immunology 137, pp. 43-44.
- Collins, F., Stone, M., Wang, E. C. Y. and Williams, A. S. 2012. Death receptor 3 and tl1a: A regulatory pathway of bone turnover and target for osteoporosis therapy? [Abstract]. Osteoporosis International 23, pp. S528-S528.
- Bonnet, C., Williams, A. S., Harvey, A., Gilbert, S. J., Moideen, A. N., Nowell, M. A. and Mason, D. J. 2012. Intra-articular AMPA/kainate glutamate receptor antagonists alleviate inflammation, pain and pathology in rat antigen induced arthritis [Abstract]. Osteoporosis International 23, pp. S527-S527.
- Moideen, A. N., Evans, L., Osgood, L. E., Williams, A., Jones, S. A. and Nowell, M. A. 2012. Nicotinamide adenine dinucleotide (NAD plus) biosynthesis enzymes in rheumatoid arthritis [Abstract]. Rhuematology 51(s3), pp. 142-142. (10.1093/rheumatology/kes108)
- Collins, F., Stone, M. D., Wang, E. C. Y. and Williams, A. S. 2012. Death receptor 3 and Tl1a: A driving force in osteoclast differentiation and potential target for rheumatoid arthritis therapy [Abstract]. Rheumatology 51(s3), pp. 140-140. (10.1093/rheumatology/kes108)
- Greenhill, C. et al. 2012. The regulation of arthritic bone erosions by il-10 [Abstract]. Rhuematology 51, pp. 48-48. (10.1093/rheumatology/kes117)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2012. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Rhuematology 51(s3), pp. 43-44. (10.1093/rheumatology/kes117)
- Nowell, M. A., Evans, L. C. and Williams, A. S. 2012. PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?. Future Medicinal Chemistry 4(6), pp. 751-769. (10.4155/fmc.12.34)
2011
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Immunology 135(S1), pp. 158. (10.1111/j.1365-2567.2011.03534.x)
- Greenhill, C. J. et al. 2011. The regulation of arthritic bone erosions by IL-10 [Abstract]. Immunology 135(s1), pp. 158-158. (10.1111/j.1365-2567.2011.03534.x)
- Wang, E. C. Y. et al. 2011. Control of early cartilage destruction in inflammatory arthritis by death receptor 3 [Abstract]. Immunology 135(s1), pp. 153-153. (10.1111/j.1365-2567.2011.03534.x)
- Bonnet, C. S., Williams, A. S., Moideen, A. N., Nowell, M. A. and Mason, D. J. 2011. Intra-articular AMPA/kainate glutamate receptor antagonists alleviate inflammation, pain and pathology in rat antigen induced arthritis [Abstract]. International Journal of Experimental Pathology 92(6), pp. A14-A14. (10.1111/j.1365-2613.2011.00780.x)
- Jones, G. W., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B- cell responses [Abstract]. Arthritis and Rheumatism 63(s10), pp. S978-S978. (10.1002/art.33310)
- Paringe, V., Bloom, A. C., Choy, E. H. S., Morgan, B. P. and Williams, A. S. 2011. Compromised expression of the complement membrane inhibitor CD59a propagates age-related joint degeneration in mice [Poster Abstract]. Arthritis and Rheumatism 63(s10), pp. S947-S947. (10.1002/art.33310)
- Smale, S., Carty, S. M., Goodfellow, R. M., Choy, E. H., Rose-John, S., Jones, S. A. and Williams, A. S. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63(s10), pp. S446-S447.
- Evans, L. C., Williams, A. S., Hayes, A. J., Jones, S. A. and Nowell, M. A. 2011. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis and Rheumatism 63(7), pp. 1866-1877. (10.1002/art.30338)
- Evans, A., Williams, A. S., Hayes, A. J. and Nowell, M. A. 2011. Investigating the role of PBEF on cartilage integrity [Abstract]. International Journal of Experimental Pathology 92(3), pp. A33-A34. (10.1111/j.1365-2613.2010.00759.x)
- Bloom, A. C., Collins, F., Evans, B. A. J., Aeschlimann, D. P., Morgan, B. P. and Williams, A. S. 2011. CD59 an unexpected protective role in bone [Abstract]. Bone 48, pp. S161-S162.
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25(1), pp. 409-419. (10.1096/fj.10-166843)
2010
- Williams, A. S., Collins, F., Newton, Z., Goodfellow, R. M., Rajak, R., Calder, C. J. and Wang, E. C. Y. 2010. Death Receptor 3 orchestrates erosive pathology in inflammatory arthritis [Poster Abstract]. Immunology 131(s1), pp. 53-53. (10.1111/j.1365-2567.2010.03390.x)
- Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131(s1), pp. 102-102. (10.1111/j.1365-2567.2010.03390.x)
- Lissilaa, R. et al. 2010. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. The Journal of Immunology 185(9), pp. 5512-5521. (10.4049/jimmunol.1002015)
- Jones, G. W. et al. 2010. Loss of CD4+ T Cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. The Journal of Immunology 184(4), pp. 2130-2139. (10.4049/jimmunol.0901528)
- Jones, G. W. et al. 2010. Loss of CD4(+) T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. Journal of Immunology 184(4), pp. 2130-2139.
- Page, C. E. et al. 2010. Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research & Therapy 12(2), article number: R49. (10.1186/ar2960)
- Richards, H. C., Williams, A. S., Jones, E., Hindley, J. P., Godkin, A. J., Simon, A. K. and Gallimore, A. M. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131(4), pp. 583-592. (10.1111/j.1365-2567.2010.03333.x)
- Page, C. E. et al. 2010. Interferon-gamma inhibits interleukin-1 beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research and Therapy 12(2), article number: R49.
2009
- Williams, A. S. et al. 2009. A functional role for death receptor-3 in arthritis [Abstract]. Cytokine 48(1-2), pp. 134-134. (10.1016/j.cyto.2009.07.568)
- Newton, Z., Bull, M., Wang, E. C. Y. and Williams, A. S. 2009. The role of dr3/tl1a in cartilage depletion caused by inflammatory arthritis [Abstract]. Rhuematology 48(s1), pp. I30-I30. (10.1093/rheumatology/kep713)
- Williams, A. S. et al. 2009. Functional role of dr3 in inflammatory arthritis: A novel target for therapy? [Abstract]. Rheumatology 48(s1), pp. I8-I8. (10.1093/rheumatology/kep704)
- Nowell, M. A. et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. Journal of Immunology 182(1), pp. 613-622.
2008
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125(s1), pp. 62-62. (10.1111/j.1365-2567.2008.02974.x)
- Williams, A. S. et al. 2008. The role of death receptor 3 in inflammatory arthritis [Abstract]. Immunology 125, pp. 34-34. (10.1111/j.1365-2567.2008.02974.x)
- Bull, M. J. et al. 2008. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. Journal of Experimental Medicine 205(11), pp. 2457-2464. (10.1084/jem.20072378)
- Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Jones, G. W. et al. 2008. TL1A negatively regulates development of T helper 17 cells [Abstract]. Rheumatology 47(S2), pp. II20-II20. (10.1093/rheumatology/kem509)
- Page, C. E. et al. 2008. Ifn gamma protects articular cartilage against IL-1 induced tissue injury in arthritis. C Page, S Smale, S Lauder, S Carty, R Goodfellow, S Jones, N Topley & A Williams. School of medicine, Cardiff University, Cardiff, CF14 4XN [Poster Abstract]. Rhuematology 47(s2), pp. II177-II177. (10.1093/rheumatology/kem534)
- Nowell, M. A. and Williams, A. S. 2008. Selective inhibition of PBEF activity with a small molecule inhibitor, APO866 ameliorates collagen-induced arthritis [Abstract]. Rheumatology 47, pp. II58-II59.
- Smale, S., Amos, N., Jones, S. A. and Williams, A. S. 2008. Local activation of STAT3 but not STAT1 during collagen induced arthritis. Correlation with local and systemic cytokine activity [Poster Abstract]. Rheumatology 47(s2), pp. II53-II53. (10.1093/rheumatology/kem514)
- Rabe, B. et al. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3), pp. 1021-1028. (10.1182/blood-2007-07-102137)
- Jones, S. A., Jones, G. W., Williams, A. S. and Nowell, M. A. 2008. Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression. Immunology Endocrine & Metabolic Agents in Medicinal Chemistry 8(3), pp. 235-246.
- Hepburn, N. J., Chamberlain-Banoub, J. L., Williams, A. S., Morgan, B. P. and Harris, C. L. 2008. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Molecular Immunology 45(2), pp. 395-405. (10.1016/j.molimm.2007.06.144)
- Hallett, M. B. and Williams, A. S. 2008. Stopping the traffic: A route to arthritis therapy. European Journal of Immunology 38(10), pp. 2650-2653. (10.1002/eji.200838786)
2007
- Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
- Jones, G. W. et al. 2007. TL1A counteracts the IL-6 control of the STAT3-mediated development of T helper 17 cells [Abstract]. Cytokine 39(1), pp. 18-19.
- Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
- Williams, A. S. et al. 2007. Interferon-γ protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis & Rheumatism 56(7), pp. 2244-2254. (10.1002/art.22732)
- Page, C. E., Smale, S., Lauder, S. N., Carty, S. M. and Williams, A. S. 2007. Interferon gamma decreases interleukin 1 beta-mediated cartilage loss in rheumatoid arthritis [Abstract]. Rheumatology 46, pp. I45-I46.
- Carty, S. M., Nowell, M. A., Lauder, S. N., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2007. Combination therapy with etanercept and sgp130 for rheumatoid arthritis is more effective than monotherapy [Abstract]. Rheumatology 46(s1), pp. I18-I18. (10.1093/rheumatology/kem1007)
- Hepburn, N. J., Williams, A. S., Morgan, B. P. and Harris, C. L. 2007. In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata. J Biol Chem 282, pp. 8292-8299. (10.1074/jbc.M609858200)
- Hepburn, N. J., Williams, A. S., Chamberlain, J. C., Hamer, J., Nunn, M. A., Morgan, B. P. and Harris, C. L. 2007. In vivo characterisation and therapeutic efficacy of a C5-specific inhibitor [Abstract]. Molecular Immunology 44(1-3), pp. 183-183. (10.1016/j.molimm.2006.07.087)
2006
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2006. TINFa and IL-6/slL-6R interactions regulate the magnitude and the phenotype of synovial Leucocyte infiltration in rheumatoid arthritis [Abstract]. Arthritis and Rheumatism 54(9), pp. S597-S597.
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
- Grau, S. et al. 2006. The role of human HtrA1 in arthritic disease. The Journal of Biological Chemistry 281(10), pp. 6124-6129. (10.1074/jbc.M500361200)
- Flood, S. J., Parri, R., Williams, A. S., Duance, V. C. and Mason, D. J. 2006. Ionotropic glutamate receptors are functional in human fibroblast-like synoviocytes and modulate IL-6 and MMP-2 expression [Abstract]. Bone 38(3), pp. S36-S36.
2005
- Richards, H. E., Simon, A. K., Jones, E., Williams, A. S., Screaton, G. R. and Gallimore, A. M. 2005. Inhibition of innate immune responses to tumours by CD4+CD25+ regulatory T cells [Abstract]. Immunology 116(s1), pp. 36-36. (10.1111/j.1365-2567.2005.02287.x)
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Redman, S., Haughton, L., Dowthwaite, G., Williams, A. S. and Archer, C. W. 2005. The effect of Notch signal inhibition on osteoarthritic micromass cultures [Abstract]. International Journal of Experimental Pathology 86(3), pp. A48-A48.
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Topley, N., Jones, S. A., Williams, B. D. and Williams, A. S. 2005. Interleukin 6 (IL-6) signalling in rheumatoid arthritis. Rheumatology 44, pp. I38-I38.
2004
- Williams, A. S., Mizuno, M., Richards, P. J., Holt, D. S. and Morgan, B. P. 2004. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis & Rheumatism 50(9), pp. 3035-3044. (10.1002/art.20478)
2003
- Williams, A. S., Fraser, D. A., Harris, C. L. and Mizuno, M. 2003. Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. The Journal of Biological Chemistry 278(49), pp. 48921-48927. (10.1074/jbc.M302598200)
- Harris, C. L., Hughes, C. E., Williams, A. S., Goodfellow, I., Evans, D. J., Caterson, B. and Morgan, B. P. 2003. Generation of anti-complement 'prodrugs': cleavable reagents for specific delivery of complement regulators to disease sites. The Journal of Biological Chemistry 278(38), pp. 36068-36076. (10.1074/jbc.M306351200)
- Nowell, M. A. et al. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. The Journal of Immunology 171(6), pp. 3202-3209.
- McLoughlin, R. M. et al. 2003. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. The Journal of Clinical Investigation 112(4), pp. 598-607. (10.1172/JCI200317129)
2001
- Davies, J. R., Williams, A. S., Akhtar, S. and Caterson, B. 2001. Appearance of a proteoglycan layer on the articular surface in murine antigen induced arthritis - Is this an accumulation of superficial zone proteoglycan (SZP)? [Poster Abstract]. International Journal of Experimental Pathology 82(6), pp. A5. (10.1046/j.1365-2613.2001.82_6am.x)
1999
- Williams, A. S., Jones, S. G., Goodfellow, R. M., Amos, N. and Williams, B. D. 1999. Interleukin-1β (IL-1β) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis. British Journal of Pharmacology 128(1), pp. 234-240. (10.1038/sj.bjp.0702776)
Adrannau llyfrau
- Morrin, A. S., Eastham, S., Williams, A. S. and Jones, G. W. 2023. Tracking cardiovascular comorbidity in models of chronic inflammatory disease. In: Jenkins, B. J. ed. Inflammation and Cancer., Vol. 2691. Methods in Molecular Biology New York, NY, USA: Springer, pp. 123-137., (10.1007/978-1-0716-3331-1_10)
- Jones, G., Hill, D., Sime, K. and Williams, A. 2018. In Vivo models for inflammatory arthritis. In: Jenkins, B. ed. Inflammation and Cancer. Methods in Molecular Biology., Vol. 1725. Methods in Molecular Biology New York, NY: Humana Press, pp. 101-118., (10.1007/978-1-4939-7568-6_9)
Erthyglau
- Gillespie, D. et al. 2022. PrEP use, sexual behaviour, and PrEP adherence among men who have sex with men living in Wales prior to and during the COVID-19 pandemic. AIDS and Behavior 26, pp. 2746-2757. (10.1007/s10461-022-03618-4)
- Davies, R. et al. 2021. The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology 60(6), pp. 2852-2861., article number: keaa725. (10.1093/rheumatology/keaa725)
- Bonnet, C. S., Gilbert, S. J., Blain, E. J., Williams, A. S. and Mason, D. J. 2020. AMPA/kainate glutamate receptor antagonists prevent posttraumatic osteoarthritis. JCI Insight 5(13), article number: e134055. (10.1172/jci.insight.134055)
- Thompson, C., Davies, R., Williams, A., Jones, G. and Choy, E. H. S. 2020. CD28− Cells are increased in early rheumatoid arthritis and are linked with cytomegalovirus status. Frontiers in Medicine 7, article number: 129. (10.3389/fmed.2020.00129)
- Collins, F. L., Stone, M. D., Turton, J., McCabe, L. R., Wang, E. C. and Williams, A. S. 2019. Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels. BMC Musculoskeletal Disorders 20(1), article number: 326. (10.1186/s12891-019-2704-z)
- Williams, A., Jones, M. G., Jonsson, R., Harris, R. A. and Mulvany, M. J. 2019. A comparison of doctoral training in biomedicine and medicine for some UK and Scandinavian graduate programmes: Learning from each other. FEBS Open Bio 9(5), pp. 830-839. (10.1002/2211-5463.12629)
- Williams, A., Powell, A. G., Spernaes, I., Basu, P., Edwards, S. and Edwards, P. 2019. Mode of presentation rather than the 'weekend effect' is a major determinant of in-hospital mortality. Surgeon 17(1), pp. 15-18. (10.1016/j.surge.2018.04.007)
- Jordan, L. A. et al. 2018. Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis. Rheumatology 57(11), pp. 2042-2052. (10.1093/rheumatology/key196)
- Tonks, A. J. and Williams, A. S. 2018. Identifying unmet training needs for postgraduate research students in the biomedical sciences through audit of examiners' reports. International Journal of Doctoral Studies 13, pp. 169-191. (10.28945/4003)
- Colbeck, E. J. et al. 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5(11), pp. 1005-1015. (10.1158/2326-6066.CIR-17-0131)
- Singh, R. et al. 2017. Death receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation. Cellular Immunology 320, pp. 62-70. (10.1016/j.cellimm.2017.09.005)
- Sime, K., Choy, E. and Williams, A. 2017. Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice. Adipocyte 6(2), pp. 87-101. (10.1080/21623945.2017.1295174)
- Collins, F. L. et al. 2017. CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss. Bone 97, pp. 94-104. (10.1016/j.bone.2017.01.002)
- Williams, A., Wang, E. C. Y., Thurner, L. and Liu, C. 2016. Novel insights into TNF receptor, DR3 and progranulin pathways in arthritis and bone remodeling. Arthritis & Rheumatology 68(12), pp. 2845-2856. (10.1002/art.39816)
- Perks, W. V. et al. 2016. Death Receptor 3 promotes chemokine directed leukocyte recruitment in acute resolving inflammation and is essential for pathological development of mesothelial fibrosis in chronic disease. American Journal of Pathology 186(11), pp. 2813-2823. (10.1016/j.ajpath.2016.07.021)
- Williams, J., Wang, E. C. Y., Lang, D. and Williams, A. S. 2016. Characterisation of Death Receptor 3 dependent aortic changes during inflammatory arthritis. Pharmacology Research & Perspectives 4(4), article number: e0024. (10.1002/prp2.240)
- Knight, J. C., Paisey, S. J., Dabkowski, A. M., Marculescu, C., Williams, A. S., Marshall, C. and Cornelissen, B. 2016. Scaling-down antibody radiolabeling reactions with zirconium-89. Dalton Transactions 45(15), pp. 6343-6347. (10.1039/C5DT04774A)
- Davies, R. et al. 2016. Serum Vascular Cell Adhesion Molecule 1 levels are associated with vascular Dysfunction and increased cardiovascular risk in an animal model and patients with Rheumatoid Arthritis. Rheumatology 55(Supp 1), pp. 54-54., article number: O41. (10.1093/rheumatology/kew102.004)
- Harvey, A. K. et al. 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2(2), article number: 33. (10.23937/2469-5726/1510033)
- Bloom, A. C. et al. 2016. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84, pp. 253-261. (10.1016/j.bone.2015.12.014)
- Jones, G. W. et al. 2015. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. Journal of Experimental Medicine 212(11), pp. 1793-1802. (10.1084/jem.20132307)
- Bonnet, C. S., Williams, A. S., Gilbert, S. J., Harvey, A. K., Evans, B. A. and Mason, D. J. 2014. AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Annals of the Rheumatic Diseases 74, pp. 242-251. (10.1136/annrheumdis-2013-203670)
- Wang, E. C. Y. et al. 2014. Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis and Rheumatology 66(10), pp. 2762-2772. (10.1002/art.38770)
- Greenhill, C. J. et al. 2014. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy 16(4), article number: 419. (10.1186/s13075-014-0419-y)
- Kehoe, O. et al. 2014. Syndecan-3 is selectively pro-inflammatory in the joint and contributes to antigen-induced arthritis in mice. Arthritis Research and Therapy 16(4), pp. 1-14., article number: R148. (10.1186/ar4610)
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Jones, G. W., Greenhill, C. J., Williams, J. O., Nowell, M. A., Williams, A. S., Jenkins, B. J. and Jones, S. A. 2013. Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. Annals of the Rheumatic Diseases 72(10), pp. 1738-1742. (10.1136/annrheumdis-2013-203771)
- Greenhill, C. J. et al. 2013. Interleukin 10 control of the inflammasome restricts arthritic bone erosion [Abstract]. Cytokine 63(3), pp. 267. (10.1016/j.cyto.2013.06.105)
- Moideen, A. N. et al. 2013. Characterization of enzymes involved in nicotinamide adenine dinucleotide biosynthesis in rheumatoid arthritis synovium and cytokine-stimulated synovial fibroblasts [Abstracts]. Rhuematology 52(s1), pp. 138-139.
- Reynolds, S. L. et al. 2012. Contractile, but not endothelial, dysfunction in early inflammatory arthritis: a possible role for matrix metalloproteinase-9. British Journal of Pharmacology 167(3), pp. 505-514. (10.1111/j.1476-5381.2012.01988.x)
- Collins, F., Stone, M. D., Goodfellow, R. M., Choy, E. H. S., Wang, E. C. Y. and Williams, A. S. 2012. TNF-like protein 1A/death receptor 3 pathway regulates osteoclastogenesis and is associated with erosive disease in rheumatoid arthritis. Arthritis and Rheumatism 64(10), pp. S768-S768.
- Greenhill, C. J. et al. 2012. Cross-talk between IL-10 and the inflammasome regulates bone erosions during rheumatoid arthritis [Abstract]. Immunology 137, pp. 43-44.
- Collins, F., Stone, M., Wang, E. C. Y. and Williams, A. S. 2012. Death receptor 3 and tl1a: A regulatory pathway of bone turnover and target for osteoporosis therapy? [Abstract]. Osteoporosis International 23, pp. S528-S528.
- Bonnet, C., Williams, A. S., Harvey, A., Gilbert, S. J., Moideen, A. N., Nowell, M. A. and Mason, D. J. 2012. Intra-articular AMPA/kainate glutamate receptor antagonists alleviate inflammation, pain and pathology in rat antigen induced arthritis [Abstract]. Osteoporosis International 23, pp. S527-S527.
- Moideen, A. N., Evans, L., Osgood, L. E., Williams, A., Jones, S. A. and Nowell, M. A. 2012. Nicotinamide adenine dinucleotide (NAD plus) biosynthesis enzymes in rheumatoid arthritis [Abstract]. Rhuematology 51(s3), pp. 142-142. (10.1093/rheumatology/kes108)
- Collins, F., Stone, M. D., Wang, E. C. Y. and Williams, A. S. 2012. Death receptor 3 and Tl1a: A driving force in osteoclast differentiation and potential target for rheumatoid arthritis therapy [Abstract]. Rheumatology 51(s3), pp. 140-140. (10.1093/rheumatology/kes108)
- Greenhill, C. et al. 2012. The regulation of arthritic bone erosions by il-10 [Abstract]. Rhuematology 51, pp. 48-48. (10.1093/rheumatology/kes117)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2012. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Rhuematology 51(s3), pp. 43-44. (10.1093/rheumatology/kes117)
- Nowell, M. A., Evans, L. C. and Williams, A. S. 2012. PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?. Future Medicinal Chemistry 4(6), pp. 751-769. (10.4155/fmc.12.34)
- Jones, G. W., Greenhill, C. J., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B-cell responses [Abstract]. Immunology 135(S1), pp. 158. (10.1111/j.1365-2567.2011.03534.x)
- Greenhill, C. J. et al. 2011. The regulation of arthritic bone erosions by IL-10 [Abstract]. Immunology 135(s1), pp. 158-158. (10.1111/j.1365-2567.2011.03534.x)
- Wang, E. C. Y. et al. 2011. Control of early cartilage destruction in inflammatory arthritis by death receptor 3 [Abstract]. Immunology 135(s1), pp. 153-153. (10.1111/j.1365-2567.2011.03534.x)
- Bonnet, C. S., Williams, A. S., Moideen, A. N., Nowell, M. A. and Mason, D. J. 2011. Intra-articular AMPA/kainate glutamate receptor antagonists alleviate inflammation, pain and pathology in rat antigen induced arthritis [Abstract]. International Journal of Experimental Pathology 92(6), pp. A14-A14. (10.1111/j.1365-2613.2011.00780.x)
- Jones, G. W., Williams, A. S., Nowell, M. A., Jenkins, B. J. and Jones, S. A. 2011. Interleukin-27 receptor-deficient mice develop exacerbated inflammatory arthritis associated with heightened T- and B- cell responses [Abstract]. Arthritis and Rheumatism 63(s10), pp. S978-S978. (10.1002/art.33310)
- Paringe, V., Bloom, A. C., Choy, E. H. S., Morgan, B. P. and Williams, A. S. 2011. Compromised expression of the complement membrane inhibitor CD59a propagates age-related joint degeneration in mice [Poster Abstract]. Arthritis and Rheumatism 63(s10), pp. S947-S947. (10.1002/art.33310)
- Smale, S., Carty, S. M., Goodfellow, R. M., Choy, E. H., Rose-John, S., Jones, S. A. and Williams, A. S. 2011. Inhibiting IL-6 trans-signalling with soluble gp130Fc potently reduces the incidence and severity of collagen-induced experimental arthritis [Abstract]. Arthritis and Rheumatism 63(s10), pp. S446-S447.
- Evans, L. C., Williams, A. S., Hayes, A. J., Jones, S. A. and Nowell, M. A. 2011. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis and Rheumatism 63(7), pp. 1866-1877. (10.1002/art.30338)
- Evans, A., Williams, A. S., Hayes, A. J. and Nowell, M. A. 2011. Investigating the role of PBEF on cartilage integrity [Abstract]. International Journal of Experimental Pathology 92(3), pp. A33-A34. (10.1111/j.1365-2613.2010.00759.x)
- Bloom, A. C., Collins, F., Evans, B. A. J., Aeschlimann, D. P., Morgan, B. P. and Williams, A. S. 2011. CD59 an unexpected protective role in bone [Abstract]. Bone 48, pp. S161-S162.
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25(1), pp. 409-419. (10.1096/fj.10-166843)
- Williams, A. S., Collins, F., Newton, Z., Goodfellow, R. M., Rajak, R., Calder, C. J. and Wang, E. C. Y. 2010. Death Receptor 3 orchestrates erosive pathology in inflammatory arthritis [Poster Abstract]. Immunology 131(s1), pp. 53-53. (10.1111/j.1365-2567.2010.03390.x)
- Jones, G. W. et al. 2010. Differential responsiveness of naive and activated T cells to TL1A that affect Th17 generation, maintenance and proliferation [Abstract]. Immunology 131(s1), pp. 102-102. (10.1111/j.1365-2567.2010.03390.x)
- Lissilaa, R. et al. 2010. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. The Journal of Immunology 185(9), pp. 5512-5521. (10.4049/jimmunol.1002015)
- Jones, G. W. et al. 2010. Loss of CD4+ T Cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. The Journal of Immunology 184(4), pp. 2130-2139. (10.4049/jimmunol.0901528)
- Jones, G. W. et al. 2010. Loss of CD4(+) T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. Journal of Immunology 184(4), pp. 2130-2139.
- Page, C. E. et al. 2010. Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research & Therapy 12(2), article number: R49. (10.1186/ar2960)
- Richards, H. C., Williams, A. S., Jones, E., Hindley, J. P., Godkin, A. J., Simon, A. K. and Gallimore, A. M. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131(4), pp. 583-592. (10.1111/j.1365-2567.2010.03333.x)
- Page, C. E. et al. 2010. Interferon-gamma inhibits interleukin-1 beta-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research and Therapy 12(2), article number: R49.
- Williams, A. S. et al. 2009. A functional role for death receptor-3 in arthritis [Abstract]. Cytokine 48(1-2), pp. 134-134. (10.1016/j.cyto.2009.07.568)
- Newton, Z., Bull, M., Wang, E. C. Y. and Williams, A. S. 2009. The role of dr3/tl1a in cartilage depletion caused by inflammatory arthritis [Abstract]. Rhuematology 48(s1), pp. I30-I30. (10.1093/rheumatology/kep713)
- Williams, A. S. et al. 2009. Functional role of dr3 in inflammatory arthritis: A novel target for therapy? [Abstract]. Rheumatology 48(s1), pp. I8-I8. (10.1093/rheumatology/kep704)
- Nowell, M. A. et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. Journal of Immunology 182(1), pp. 613-622.
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125(s1), pp. 62-62. (10.1111/j.1365-2567.2008.02974.x)
- Williams, A. S. et al. 2008. The role of death receptor 3 in inflammatory arthritis [Abstract]. Immunology 125, pp. 34-34. (10.1111/j.1365-2567.2008.02974.x)
- Bull, M. J. et al. 2008. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. Journal of Experimental Medicine 205(11), pp. 2457-2464. (10.1084/jem.20072378)
- Rabe, B. et al. 2008. The role of IL6-transsignaling in acute and chronic inflammation [Abstract]. Cytokine 43(3), pp. 244-244. (10.1016/j.cyto.2008.07.073)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Jones, G. W. et al. 2008. TL1A negatively regulates development of T helper 17 cells [Abstract]. Rheumatology 47(S2), pp. II20-II20. (10.1093/rheumatology/kem509)
- Page, C. E. et al. 2008. Ifn gamma protects articular cartilage against IL-1 induced tissue injury in arthritis. C Page, S Smale, S Lauder, S Carty, R Goodfellow, S Jones, N Topley & A Williams. School of medicine, Cardiff University, Cardiff, CF14 4XN [Poster Abstract]. Rhuematology 47(s2), pp. II177-II177. (10.1093/rheumatology/kem534)
- Nowell, M. A. and Williams, A. S. 2008. Selective inhibition of PBEF activity with a small molecule inhibitor, APO866 ameliorates collagen-induced arthritis [Abstract]. Rheumatology 47, pp. II58-II59.
- Smale, S., Amos, N., Jones, S. A. and Williams, A. S. 2008. Local activation of STAT3 but not STAT1 during collagen induced arthritis. Correlation with local and systemic cytokine activity [Poster Abstract]. Rheumatology 47(s2), pp. II53-II53. (10.1093/rheumatology/kem514)
- Rabe, B. et al. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3), pp. 1021-1028. (10.1182/blood-2007-07-102137)
- Jones, S. A., Jones, G. W., Williams, A. S. and Nowell, M. A. 2008. Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression. Immunology Endocrine & Metabolic Agents in Medicinal Chemistry 8(3), pp. 235-246.
- Hepburn, N. J., Chamberlain-Banoub, J. L., Williams, A. S., Morgan, B. P. and Harris, C. L. 2008. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Molecular Immunology 45(2), pp. 395-405. (10.1016/j.molimm.2007.06.144)
- Hallett, M. B. and Williams, A. S. 2008. Stopping the traffic: A route to arthritis therapy. European Journal of Immunology 38(10), pp. 2650-2653. (10.1002/eji.200838786)
- Rabe, B. et al. 2007. IL6/sIL6R-transsignaling controls innate and aquired immunity [Abstract]. Cytokine 39(1), pp. 34-34. (10.1016/j.cyto.2007.07.129)
- Jones, G. W. et al. 2007. TL1A counteracts the IL-6 control of the STAT3-mediated development of T helper 17 cells [Abstract]. Cytokine 39(1), pp. 18-19.
- Hams, E. et al. 2007. Oncostatin M receptor signalling regulates monocytic cell trafficking during acute inflammation [Abstract]. Cytokine 39(1), pp. 14-14. (10.1016/j.cyto.2007.07.053)
- Williams, A. S. et al. 2007. Interferon-γ protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis & Rheumatism 56(7), pp. 2244-2254. (10.1002/art.22732)
- Page, C. E., Smale, S., Lauder, S. N., Carty, S. M. and Williams, A. S. 2007. Interferon gamma decreases interleukin 1 beta-mediated cartilage loss in rheumatoid arthritis [Abstract]. Rheumatology 46, pp. I45-I46.
- Carty, S. M., Nowell, M. A., Lauder, S. N., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2007. Combination therapy with etanercept and sgp130 for rheumatoid arthritis is more effective than monotherapy [Abstract]. Rheumatology 46(s1), pp. I18-I18. (10.1093/rheumatology/kem1007)
- Hepburn, N. J., Williams, A. S., Morgan, B. P. and Harris, C. L. 2007. In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata. J Biol Chem 282, pp. 8292-8299. (10.1074/jbc.M609858200)
- Hepburn, N. J., Williams, A. S., Chamberlain, J. C., Hamer, J., Nunn, M. A., Morgan, B. P. and Harris, C. L. 2007. In vivo characterisation and therapeutic efficacy of a C5-specific inhibitor [Abstract]. Molecular Immunology 44(1-3), pp. 183-183. (10.1016/j.molimm.2006.07.087)
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Jones, S. A., Williams, B. D. and Williams, A. S. 2006. TINFa and IL-6/slL-6R interactions regulate the magnitude and the phenotype of synovial Leucocyte infiltration in rheumatoid arthritis [Abstract]. Arthritis and Rheumatism 54(9), pp. S597-S597.
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
- Grau, S. et al. 2006. The role of human HtrA1 in arthritic disease. The Journal of Biological Chemistry 281(10), pp. 6124-6129. (10.1074/jbc.M500361200)
- Flood, S. J., Parri, R., Williams, A. S., Duance, V. C. and Mason, D. J. 2006. Ionotropic glutamate receptors are functional in human fibroblast-like synoviocytes and modulate IL-6 and MMP-2 expression [Abstract]. Bone 38(3), pp. S36-S36.
- Richards, H. E., Simon, A. K., Jones, E., Williams, A. S., Screaton, G. R. and Gallimore, A. M. 2005. Inhibition of innate immune responses to tumours by CD4+CD25+ regulatory T cells [Abstract]. Immunology 116(s1), pp. 36-36. (10.1111/j.1365-2567.2005.02287.x)
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Redman, S., Haughton, L., Dowthwaite, G., Williams, A. S. and Archer, C. W. 2005. The effect of Notch signal inhibition on osteoarthritic micromass cultures [Abstract]. International Journal of Experimental Pathology 86(3), pp. A48-A48.
- Carty, S. M., Nowell, M. A., Goodfellow, R. M., Topley, N., Jones, S. A., Williams, B. D. and Williams, A. S. 2005. Interleukin 6 (IL-6) signalling in rheumatoid arthritis. Rheumatology 44, pp. I38-I38.
- Williams, A. S., Mizuno, M., Richards, P. J., Holt, D. S. and Morgan, B. P. 2004. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis & Rheumatism 50(9), pp. 3035-3044. (10.1002/art.20478)
- Williams, A. S., Fraser, D. A., Harris, C. L. and Mizuno, M. 2003. Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. The Journal of Biological Chemistry 278(49), pp. 48921-48927. (10.1074/jbc.M302598200)
- Harris, C. L., Hughes, C. E., Williams, A. S., Goodfellow, I., Evans, D. J., Caterson, B. and Morgan, B. P. 2003. Generation of anti-complement 'prodrugs': cleavable reagents for specific delivery of complement regulators to disease sites. The Journal of Biological Chemistry 278(38), pp. 36068-36076. (10.1074/jbc.M306351200)
- Nowell, M. A. et al. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. The Journal of Immunology 171(6), pp. 3202-3209.
- McLoughlin, R. M. et al. 2003. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. The Journal of Clinical Investigation 112(4), pp. 598-607. (10.1172/JCI200317129)
- Davies, J. R., Williams, A. S., Akhtar, S. and Caterson, B. 2001. Appearance of a proteoglycan layer on the articular surface in murine antigen induced arthritis - Is this an accumulation of superficial zone proteoglycan (SZP)? [Poster Abstract]. International Journal of Experimental Pathology 82(6), pp. A5. (10.1046/j.1365-2613.2001.82_6am.x)
- Williams, A. S., Jones, S. G., Goodfellow, R. M., Amos, N. and Williams, B. D. 1999. Interleukin-1β (IL-1β) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis. British Journal of Pharmacology 128(1), pp. 234-240. (10.1038/sj.bjp.0702776)
- Collins, F. L., Stone, M. D., Turton, J., McCabe, L. R., Wang, E. C. and Williams, A. S. 2019. Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels. BMC Musculoskeletal Disorders 20(1), article number: 326. (10.1186/s12891-019-2704-z)
- Williams, A., Jones, M. G., Jonsson, R., Harris, R. A. and Mulvany, M. J. 2019. A comparison of doctoral training in biomedicine and medicine for some UK and Scandinavian graduate programmes: Learning from each other. FEBS Open Bio 9(5), pp. 830-839. (10.1002/2211-5463.12629)
- Jordan, L. A. et al. 2018. Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis. Rheumatology 57(11), pp. 2042-2052. (10.1093/rheumatology/key196)
- Tonks, A. J. and Williams, A. S. 2018. Identifying unmet training needs for postgraduate research students in the biomedical sciences through audit of examiners' reports. International Journal of Doctoral Studies 13, pp. 169-191. (10.28945/4003)
- Jones, G., Hill, D., Sime, K. and Williams, A. 2018. In Vivo models for inflammatory arthritis. In: Jenkins, B. ed. Inflammation and Cancer. Methods in Molecular Biology., Vol. 1725. Methods in Molecular Biology New York, NY: Humana Press, pp. 101-118., (10.1007/978-1-4939-7568-6_9)
- Colbeck, E. J. et al. 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5(11), pp. 1005-1015. (10.1158/2326-6066.CIR-17-0131)
- Singh, R. et al. 2017. Death receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation. Cellular Immunology 320, pp. 62-70. (10.1016/j.cellimm.2017.09.005)
- Sime, K., Choy, E. and Williams, A. 2017. Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice. Adipocyte 6(2), pp. 87-101. (10.1080/21623945.2017.1295174)
- Collins, F. L. et al. 2017. CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss. Bone 97, pp. 94-104. (10.1016/j.bone.2017.01.002)
- Williams, A., Wang, E. C. Y., Thurner, L. and Liu, C. 2016. Novel insights into TNF receptor, DR3 and progranulin pathways in arthritis and bone remodeling. Arthritis & Rheumatology 68(12), pp. 2845-2856. (10.1002/art.39816)
- Perks, W. V. et al. 2016. Death Receptor 3 promotes chemokine directed leukocyte recruitment in acute resolving inflammation and is essential for pathological development of mesothelial fibrosis in chronic disease. American Journal of Pathology 186(11), pp. 2813-2823. (10.1016/j.ajpath.2016.07.021)
- Williams, J., Wang, E. C. Y., Lang, D. and Williams, A. S. 2016. Characterisation of Death Receptor 3 dependent aortic changes during inflammatory arthritis. Pharmacology Research & Perspectives 4(4), article number: e0024. (10.1002/prp2.240)
- Knight, J. C., Paisey, S. J., Dabkowski, A. M., Marculescu, C., Williams, A. S., Marshall, C. and Cornelissen, B. 2016. Scaling-down antibody radiolabeling reactions with zirconium-89. Dalton Transactions 45(15), pp. 6343-6347. (10.1039/C5DT04774A)
- Harvey, A. K. et al. 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2(2), article number: 33. (10.23937/2469-5726/1510033)
- Bloom, A. C. et al. 2016. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84, pp. 253-261. (10.1016/j.bone.2015.12.014)
- Jones, G. W. et al. 2015. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. Journal of Experimental Medicine 212(11), pp. 1793-1802. (10.1084/jem.20132307)
- Bonnet, C. S., Williams, A. S., Gilbert, S. J., Harvey, A. K., Evans, B. A. and Mason, D. J. 2014. AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Annals of the Rheumatic Diseases 74, pp. 242-251. (10.1136/annrheumdis-2013-203670)
- Wang, E. C. Y. et al. 2014. Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis and Rheumatology 66(10), pp. 2762-2772. (10.1002/art.38770)
- Greenhill, C. J. et al. 2014. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy 16(4), article number: 419. (10.1186/s13075-014-0419-y)
- Kehoe, O. et al. 2014. Syndecan-3 is selectively pro-inflammatory in the joint and contributes to antigen-induced arthritis in mice. Arthritis Research and Therapy 16(4), pp. 1-14., article number: R148. (10.1186/ar4610)
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
- Jones, G. W., Greenhill, C. J., Williams, J. O., Nowell, M. A., Williams, A. S., Jenkins, B. J. and Jones, S. A. 2013. Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. Annals of the Rheumatic Diseases 72(10), pp. 1738-1742. (10.1136/annrheumdis-2013-203771)
- Reynolds, S. L. et al. 2012. Contractile, but not endothelial, dysfunction in early inflammatory arthritis: a possible role for matrix metalloproteinase-9. British Journal of Pharmacology 167(3), pp. 505-514. (10.1111/j.1476-5381.2012.01988.x)
- Nowell, M. A., Evans, L. C. and Williams, A. S. 2012. PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?. Future Medicinal Chemistry 4(6), pp. 751-769. (10.4155/fmc.12.34)
- Evans, L. C., Williams, A. S., Hayes, A. J., Jones, S. A. and Nowell, M. A. 2011. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis and Rheumatism 63(7), pp. 1866-1877. (10.1002/art.30338)
- Jones, G. W. et al. 2011. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. The FASEB Journal 25(1), pp. 409-419. (10.1096/fj.10-166843)
- Lissilaa, R. et al. 2010. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. The Journal of Immunology 185(9), pp. 5512-5521. (10.4049/jimmunol.1002015)
- Jones, G. W. et al. 2010. Loss of CD4+ T Cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. The Journal of Immunology 184(4), pp. 2130-2139. (10.4049/jimmunol.0901528)
- Jones, G. W. et al. 2010. Loss of CD4(+) T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. Journal of Immunology 184(4), pp. 2130-2139.
- Page, C. E. et al. 2010. Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis. Arthritis Research & Therapy 12(2), article number: R49. (10.1186/ar2960)
- Richards, H. C., Williams, A. S., Jones, E., Hindley, J. P., Godkin, A. J., Simon, A. K. and Gallimore, A. M. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131(4), pp. 583-592. (10.1111/j.1365-2567.2010.03333.x)
- Nowell, M. A. et al. 2009. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. Journal of Immunology 182(1), pp. 613-622.
- Bull, M. J. et al. 2008. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. Journal of Experimental Medicine 205(11), pp. 2457-2464. (10.1084/jem.20072378)
- Hams, E. et al. 2008. Oncostatin M receptor-β signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Hams, E. et al. 2008. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. Journal of Immunology 181(3), pp. 2174-2180.
- Rabe, B. et al. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3), pp. 1021-1028. (10.1182/blood-2007-07-102137)
- Jones, S. A., Jones, G. W., Williams, A. S. and Nowell, M. A. 2008. Appreciating the balance between classical interleukin (IL)-6 receptor signaling and IL-6 trans-signaling: implications for arthritis progression. Immunology Endocrine & Metabolic Agents in Medicinal Chemistry 8(3), pp. 235-246.
- Hepburn, N. J., Chamberlain-Banoub, J. L., Williams, A. S., Morgan, B. P. and Harris, C. L. 2008. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Molecular Immunology 45(2), pp. 395-405. (10.1016/j.molimm.2007.06.144)
- Hallett, M. B. and Williams, A. S. 2008. Stopping the traffic: A route to arthritis therapy. European Journal of Immunology 38(10), pp. 2650-2653. (10.1002/eji.200838786)
- Williams, A. S. et al. 2007. Interferon-γ protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. Arthritis & Rheumatism 56(7), pp. 2244-2254. (10.1002/art.22732)
- Hepburn, N. J., Williams, A. S., Morgan, B. P. and Harris, C. L. 2007. In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata. J Biol Chem 282, pp. 8292-8299. (10.1074/jbc.M609858200)
- Nowell, M. A. et al. 2006. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis & Rheumatism 54(7), pp. 2084-2095. (10.1002/art.21942)
- Richards, P. J. et al. 2006. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis & Rheumatism 54(5), pp. 1662-1672. (10.1002/art.21818)
- Grau, S. et al. 2006. The role of human HtrA1 in arthritic disease. The Journal of Biological Chemistry 281(10), pp. 6124-6129. (10.1074/jbc.M500361200)
- McLoughlin, R. M. et al. 2005. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 102(27), pp. 9589-9594. (10.1073/pnas.0501794102)
- Williams, A. S., Mizuno, M., Richards, P. J., Holt, D. S. and Morgan, B. P. 2004. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis & Rheumatism 50(9), pp. 3035-3044. (10.1002/art.20478)
- Williams, A. S., Fraser, D. A., Harris, C. L. and Mizuno, M. 2003. Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. The Journal of Biological Chemistry 278(49), pp. 48921-48927. (10.1074/jbc.M302598200)
- Harris, C. L., Hughes, C. E., Williams, A. S., Goodfellow, I., Evans, D. J., Caterson, B. and Morgan, B. P. 2003. Generation of anti-complement 'prodrugs': cleavable reagents for specific delivery of complement regulators to disease sites. The Journal of Biological Chemistry 278(38), pp. 36068-36076. (10.1074/jbc.M306351200)
- Nowell, M. A. et al. 2003. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. The Journal of Immunology 171(6), pp. 3202-3209.
- McLoughlin, R. M. et al. 2003. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. The Journal of Clinical Investigation 112(4), pp. 598-607. (10.1172/JCI200317129)
- Williams, A. S., Jones, S. G., Goodfellow, R. M., Amos, N. and Williams, B. D. 1999. Interleukin-1β (IL-1β) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis. British Journal of Pharmacology 128(1), pp. 234-240. (10.1038/sj.bjp.0702776)
Ymchwil
An overview by the Office of National Statistics in July 2017 stated that the UK population is getting older with 18% aged 65 and over and 2.4% aged 85. How can we ensure that people remain active and healthy as they get older?
My research focuses on the identification of cell-associated signals that underpin the development of disease in the skeletal system (e.g., cartilage and bone) and the circulatory system (e.g, arteries and heart). Arthritis is a common condition that causes pain and inflammation in a joint. In the UK, around 10 million people have arthritis and 7 million people fight their daily battles with heart and circulatory disease. I lead innovative projects aimed at the development of medicines that manipulate the inflammatory response and the processes that orchestrate tissue destruction so that an environment for repair and regeneration is restored and maintained. I am a Pharmacist with specialist knowledge of Pharmacology and Therapeutics and research strengths that span broader disciplines in the Life Sciences e.g., Immunology, Biochemistry, Cell Biology and Biomedical Imaging. In leading the pre-clinical ‘discovery’ platform in the section of Rheumatology I develop pharmacological targets and innovative research tools for translation to the clinic.
Having rheumatoid arthritis doubles the risk of most heart problems, including heart attack, stroke and atherosclerosis. Making sense of how inflammation and other risk factors influence heart disease related to rheumatoid arthritis will help doctors identify and treat high-risk patients early, before they develop symptoms. My research will provide new insights into disease mechanisms, enable better tailoring of existing treatments and pave the way for the development of new treatments and/or diagnostics.
Current projects
- Mechanisms of vascular dysfunction in rheumatoid arthritis
- Assessment of osteoclast activation inhibitors for inflammatory arthritis therapy
- Sensing bone erosion by capacitance
- Glutamate receptor antagonists for osteoarthritis therapy
- How do cytokines signalling through the transcription factors STAT1 and STAT3 determine the course of synovial inflammation?
Recent successful funding applications
- 2017: Medical Research Council (MRC) Proximity to Discovery Scheme (Biomedical Catalyst)
- 2017: Bio-Cancer Treatment International Limited (Cardiff University research and development co-operative agreement)
- 2016: MRC Proximity to Discovery Scheme (Biomedical Catalyst)
- 2016: MRC Confidence in Concept grant with SEDA Pharmaceutical Development Services
- 2016: Arthritis Research UK Centre Grant Renewal
- 2016: BBSRC (iCASE) PhD studentship with Rothamsted
- 2015: Arthritis Research UK Programme Grant
- 2014: The Elizabeth Owens Bequest PhD studentship
- 2014: Arthritis Research UK Clinical Research Fellowship
- 2014: Arthritis Research UK Experimental Arthritis Treatment Centre Grant
- 2013: British Heart Foundation (BHF) PhD Studentship
- 2013: Arthritis Research UK Project Grant
- 2013: Ferring Pharmaceutical Award
- 2012: Cardiff University President's Research Scholarship
- 2012: Arthritis Research UK Equipment Grant
- 2012: Arthritis Research UK Programme Grant
Research supervision is often regarded as an adjunct of research where it is assumed that effective researchers can supervise. My pedagogic approach recognises that supervision is a subtle and complex form of teaching that must be adapted to the individual needs of each student.
Current Postgraduate Researchers
- 2016 - present: Ewan Richardson, PhD full time
- 2015 - present: David Hill, PhD full time
- 2015 - present: David Hodson, MPhil full time
- 2014 - present: Katie Sime, PhD full time
- 2014 - present: Charlotte Rawlings, MD full time
- 2014 - present: Ruth Davies, PhD full time
Celebrating the success of my past students
- 2013 - 2016: Jessica Williams, PhD
- 2012 - 2016: Lauren Jordan, PhD
- 2011 - 2016: Abdul Moideen, MD
- 2009 - 2013: Fraser Collins, PhD
- 2009 - 2013: Laura Evans, PhD
- 2008 - 2012: Anja Bloom, PhD
- 2007 - 2009: Shaun Smale, MD
- 2006 - 2010: Sophie Reynolds, PhD
- 2006 - 2010: ZaraBeth Newton, PhD
- 2004 - 2009: Melanie Bull, PhD
- 2004 - 2009: Eleanor Carpenter, MD
- 2003 - 2008: Sarah Cartey, PhD
- 2003 - 2007: Sarah Lauder, PhD
- 1999 - 2003: Heather Mason, PhD
Congratulations!
Addysgu
As a mentor, supervisor, lecturer, module designer and Director of Postgraduate Research studies; I teach and support learning through successful engagement with a broad spectrum of teaching activities. During the course of my career (over 2 decades), I have maintained an upward and productive teaching and research portfolio that demonstrates a sustained contribution to teaching and learning excellence. I am an opportunistic learner who builds upon core knowledge through participating in continuous professional development activities. Examples include:
- 2014 - 2015: Practical Leadership for University Management
- 2013: Postgraduate Certificate in Education (PGCE)
- 2012: Medical Education Orientation Programme
- 2011: in house training for small group teaching,
- 2012: Academic mentor training(2012) and (2014/15)
A sense of personal satisfaction and self-worth is sufficient to motivate me to implement good practice and sustained inspirational teaching in training and management roles in the School of Medicine. In recognition of my standing I have served as external examiner at several UK universities:-
- 2016: University of Southampton PhD Examination Board
- 2010 - 2014: University of Surrey BSc in Microbial & Cellular Sciences,
- 2010 - 2014: University of Surrey BSc in Biochemistry
- 2010 - 2014: University of Surrey BSc in Physiology and Nutritional Sciences
- 2014: Keele University PhD Examination Board
The endorsement of my teaching portfolio by the Higher Eductation Academy has inspired other early stage career scientists and postgraduate researchers to do likewise. I support and mentor postgraduate researchers to gain recognition for their teaching activity at associate fellow level.
My teaching and learning portfolio is multi-faceted. I use both conventional and student-centred learning approaches to teach medical undergraduates, undergraduate pharmacologists and postgraduate researchers specializing in Medicine, Biological and Life Sciences. I pay explicit attention to meeting the needs of individual students/researchers and use their feedback to develop appropriate and impactful teaching/training.
Bywgraffiad
Qualifications
|
PGCE with Distinction: University of Wales, Newport |
2003 |
|
PhD: University of Wales, Cardiff |
1990 |
|
BPharm, First Class (with honours): University of Wales Institute of Science and Technology. The Sterling Winthrop Prize for achieving best grades in pharmaceutical chemistry and in pharmacology. |
1985 |
Present & previous leadership roles
- Aug'17 - present: Professor, Cardiff University School of Medicine
- May'15 - Apr'20: Deputy Dean of Research responsible for Postgraduate Research
- Jan'14 - Dec'17: Director of Postgraduate Research Studies
- Dec'12 - Dec'13: Deputy Director of Postgraduate Research Studies
- Apr'06 - Dec'10: Head of Department (Rheumatology)
Career overview
- 1990 - present: Cardiff University School of Medicine
- 2017 - present: Professor of Experimental Pharmacology and Therapeutics
- 2009 - 2017: Reader (Division of Infection and Immunity)
- 2003 - 2009: Senior Lecturer (Section of Rheumatology)
- 1999 - 2003: Non-Clinical Lecturer
- 1995 - 1999: Senior Research Scientist (Rheumatology)
- 1993 - 1995: University of Wales Fellow
- 1990 - 1993: Postdoctoral Research Fellow
Anrhydeddau a dyfarniadau
- Cardiff University STAR Award for Inspirational Leadership in Research, 2016
- Arthritis Research UK College of Experts, 2016
- Senior Fellow of the Higher Education Academy (SFHEA), 2015
- National Finalist: Science and Technology ‘Inspire Wales Award’ by Welsh Government (Institute of Welsh Affairs), 2013
- Winner: Cardiff University ‘Excellence in Teaching’ award (student nominated), 2011
Aelodaethau proffesiynol
- Member of UK Council for Graduate Education, 2013 to present
- Member of The British Society for Matrix Biology, 2011 to present
- Member of the Royal Pharmaceutical Society of Great Britain (MRPharmS), 1986 to present
Membership of peer review panels
- Expert Reviewer for the French Agence Nationale Recherche (The French National Research Agency), 2017
- Expert Reviewer for the European Commission and the European Federation of Pharmaceutical Industries, 2016
- Expert external reviewer for EU-funded William Harvey International Translational Research Academy at Barts and The London, Queen Mary School of Medicine and Dentistry. Topic: Innate immunity and inflammation/Biological basis of immunity related disorders.
Pwyllgorau ac adolygu
I lead the implementation of positive change to the University’s research environment, research training and research governance by servicing the following decision forums:-
- 2016 - present: Doctoral Academy Postgraduate Research Network
- 2015 - present: Knowledge Economy Skills Scholarship review panel
- 2013 - present: College Forum for Directors of Postgraduate Research
- 2012 - present: Postgraduate Open Day Steering Group
- 2013 - present: MRC DTP panel for supplement review
- 2016: Establishment Licence Holders’ Advisory Group (Project licence holder representative) working on behalf of Cardiff University’s Animal Welfare Ethical Review Board
- 2016: College of Physical Sciences & Engineering College’s ARE Committee that reviewed and evaluated ARE Reports for each School in the College.
- 2014 - 2015: University Task and Finish Groups to overhaul University regulations relating to ‘joint’ PhD provision and PGR Appeals procedures
- 2013 - 2015: BBSRC SWBio project sift and student interview panels
- 2013 - 2015: MRC DTP PhD project review and selection panel and student selection panel member.
- 2012 - 2016: Research Student Progress Monitoring Project Team: to create a bespoke electronic student information management system
- 2012 -2016: University Graduate College Postgraduate Research Network
- 2012 - 2016: Assuring a Quality Experience Programme Team
School committees:
- Research Degrees Committee (Chair)
- Research Management Group
- School Board
- Education Committee
- Public Understanding of Science in Health Committee
- Athena SWAN panel
- Masters in Research Programme Board (to 2015)
Reviewing
- Grant reviewer for: Orthopaedic Research UK, Arthritis Research UK, Joint Action, Wellcome Trust, Medical Research Charity, French Agence Nationale Recherche, European Commission and the European Federation of Pharmaceutical Industries.
- Reviewer of research manuscripts/articles for multiple National/International Immunology, Pharmacology, Biochemistry and Rheumatology themed research journals.
